MA55199B1 - (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques - Google Patents
(n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiquesInfo
- Publication number
- MA55199B1 MA55199B1 MA55199A MA55199A MA55199B1 MA 55199 B1 MA55199 B1 MA 55199B1 MA 55199 A MA55199 A MA 55199A MA 55199 A MA55199 A MA 55199A MA 55199 B1 MA55199 B1 MA 55199B1
- Authority
- MA
- Morocco
- Prior art keywords
- leucine
- pharmaceutically acceptable
- acceptable salt
- acetyl
- brain injury
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne des procédés de traitement de maladies, de troubles, d'états ou de syndromes, par exemple d'une lésion cérébrale traumatique, chez un patient en ayant besoin par l'administration d'une quantité thérapeutiquement efficace de DL-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, de L-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, de D-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, d'un ester d'éthyle de L-leucine, ou d'un sel pharmaceutiquement acceptable de celui-ci, d'acétyl-DL-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, d'acétyl-D-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci, ou d'acétyl-L-leucine, ou d'un sel pharmaceutiquement acceptable de celle-ci.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962812987P | 2019-03-02 | 2019-03-02 | |
| US201962842296P | 2019-05-02 | 2019-05-02 | |
| US201962888894P | 2019-08-19 | 2019-08-19 | |
| US201962895144P | 2019-09-03 | 2019-09-03 | |
| EP20712029.6A EP3934637B1 (fr) | 2019-03-02 | 2020-03-02 | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques |
| PCT/IB2020/051767 WO2020178721A1 (fr) | 2019-03-02 | 2020-03-02 | Leucine, acétyl leucine et analogues apparentés pour le traitement d'une maladie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA55199A MA55199A (fr) | 2022-01-12 |
| MA55199B1 true MA55199B1 (fr) | 2024-08-30 |
Family
ID=69845470
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA55199A MA55199B1 (fr) | 2019-03-02 | 2020-03-02 | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20220142959A1 (fr) |
| EP (2) | EP4464378A3 (fr) |
| JP (2) | JP7555346B2 (fr) |
| KR (2) | KR102941068B1 (fr) |
| CN (2) | CN119097618A (fr) |
| AU (2) | AU2020231189B2 (fr) |
| BR (1) | BR112021017203A2 (fr) |
| CA (1) | CA3131948A1 (fr) |
| DK (1) | DK3934637T3 (fr) |
| ES (1) | ES2990183T3 (fr) |
| FI (1) | FI3934637T3 (fr) |
| HR (1) | HRP20241150T1 (fr) |
| HU (1) | HUE068527T2 (fr) |
| IL (2) | IL321899A (fr) |
| LT (1) | LT3934637T (fr) |
| MA (1) | MA55199B1 (fr) |
| MD (1) | MD3934637T2 (fr) |
| MX (2) | MX2021010568A (fr) |
| PL (1) | PL3934637T3 (fr) |
| PT (1) | PT3934637T (fr) |
| RS (1) | RS65849B1 (fr) |
| SG (1) | SG11202109512SA (fr) |
| SI (1) | SI3934637T1 (fr) |
| SM (1) | SMT202400334T1 (fr) |
| WO (1) | WO2020178721A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| EP3886986A1 (fr) * | 2018-12-06 | 2021-10-06 | IntraBio Ltd | Analogues deutérés d'acétyl-leucine |
| US20250025442A1 (en) * | 2020-12-10 | 2025-01-23 | Texas Tech University System | BCAA-Lowering Compounds for Prevention and/or Treatment of Alzheimer's Disease and Related Disorders |
| WO2022264037A1 (fr) * | 2021-06-14 | 2022-12-22 | Intrabio Ltd. | Dérivés d'acides aminés à chaîne ramifiée pour traiter une maladie |
| WO2024243004A2 (fr) * | 2023-05-19 | 2024-11-28 | The Children's Hospital Of Philadelphia | Compositions et procédés de traitement d'une lésion cérébrale traumatique |
| US12403111B2 (en) | 2024-02-02 | 2025-09-02 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
| WO2025175092A1 (fr) * | 2024-02-14 | 2025-08-21 | Intrabio Inc. | Acétylleucine pour le traitement de troubles liés à syngap1 |
| WO2025264957A2 (fr) * | 2024-06-20 | 2025-12-26 | Intrabio Inc. | Acétyl leucine pour le traitement de troubles neurodéveloppementaux |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| LT2588130T (lt) | 2010-06-25 | 2016-12-12 | Shire Human Genetic Therapies, Inc. | Terapinės priemonės pristatymas cns |
| US20140080885A1 (en) * | 2012-09-13 | 2014-03-20 | University Of South Florida (A Florida Non-Profit Corporation) | Methods of treating traumatic brain injury |
| ES2994242T3 (en) * | 2016-04-19 | 2025-02-05 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility |
| TN2016000259A1 (en) * | 2016-06-27 | 2017-10-06 | Rekik Raouf | Salbutamol (albuterol) eye protective medicament. |
| WO2018029658A1 (fr) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Agents thérapeutiques pour maladies neurodégénératives |
| DK3359146T3 (en) | 2016-08-11 | 2019-04-08 | Intrabio Ltd | PHARMACEUTICAL COMPOSITIONS AND USES AGAINST LYSOSOMAL STORAGE DISEASES |
| JP7370960B2 (ja) * | 2017-08-14 | 2023-10-30 | アクセラ・ヘルス・インコーポレイテッド | 神経細胞損傷の治療のためのアミノ酸組成物 |
-
2020
- 2020-03-02 SM SM20240334T patent/SMT202400334T1/it unknown
- 2020-03-02 MX MX2021010568A patent/MX2021010568A/es unknown
- 2020-03-02 PT PT207120296T patent/PT3934637T/pt unknown
- 2020-03-02 ES ES20712029T patent/ES2990183T3/es active Active
- 2020-03-02 MD MDE20220032T patent/MD3934637T2/ro unknown
- 2020-03-02 IL IL321899A patent/IL321899A/en unknown
- 2020-03-02 SI SI202030476T patent/SI3934637T1/sl unknown
- 2020-03-02 CA CA3131948A patent/CA3131948A1/fr active Pending
- 2020-03-02 BR BR112021017203A patent/BR112021017203A2/pt unknown
- 2020-03-02 PL PL20712029.6T patent/PL3934637T3/pl unknown
- 2020-03-02 AU AU2020231189A patent/AU2020231189B2/en active Active
- 2020-03-02 WO PCT/IB2020/051767 patent/WO2020178721A1/fr not_active Ceased
- 2020-03-02 FI FIEP20712029.6T patent/FI3934637T3/fi active
- 2020-03-02 RS RS20240913A patent/RS65849B1/sr unknown
- 2020-03-02 SG SG11202109512SA patent/SG11202109512SA/en unknown
- 2020-03-02 CN CN202411228005.XA patent/CN119097618A/zh active Pending
- 2020-03-02 MA MA55199A patent/MA55199B1/fr unknown
- 2020-03-02 US US17/435,784 patent/US20220142959A1/en active Pending
- 2020-03-02 EP EP24188941.9A patent/EP4464378A3/fr active Pending
- 2020-03-02 JP JP2021551939A patent/JP7555346B2/ja active Active
- 2020-03-02 KR KR1020217031422A patent/KR102941068B1/ko active Active
- 2020-03-02 KR KR1020257040124A patent/KR20250171484A/ko active Pending
- 2020-03-02 IL IL285870A patent/IL285870B2/en unknown
- 2020-03-02 HU HUE20712029A patent/HUE068527T2/hu unknown
- 2020-03-02 CN CN202080029158.5A patent/CN114040757B/zh active Active
- 2020-03-02 DK DK20712029.6T patent/DK3934637T3/da active
- 2020-03-02 LT LTEPPCT/IB2020/051767T patent/LT3934637T/lt unknown
- 2020-03-02 HR HRP20241150TT patent/HRP20241150T1/hr unknown
- 2020-03-02 EP EP20712029.6A patent/EP3934637B1/fr active Active
-
2021
- 2021-09-02 MX MX2024015063A patent/MX2024015063A/es unknown
-
2024
- 2024-09-10 JP JP2024155453A patent/JP2024170602A/ja active Pending
-
2025
- 2025-06-30 AU AU2025204995A patent/AU2025204995A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55199B1 (fr) | (n-)acétyl-l-leucine pour le traitement des lésions cérébrales traumatiques | |
| EA201790406A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| MXPA04004552A (es) | Compuestos tipo indolizina sustituida y metodos de uso. | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| EA202190586A1 (ru) | N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6 | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| ZA202205149B (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| WO2023081482A9 (fr) | Association de sodium phénylbutyrate et de taurursodiol pour le traitement de maladies neurodégénératives | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX2020013692A (es) | Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma. | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| TN2010000108A1 (fr) | Traitement de symtomes vasomoteurs | |
| MX2022006052A (es) | Inhibidores de la caspasa 6 y usos de los mismos. | |
| MA53372B1 (fr) | Pyridopyrimidinones comme inhibiteurs du récepteur h4 de l'histamine | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| JP2021521227A5 (fr) | ||
| WO2022048618A8 (fr) | Méthodes de traitement des maladies inflammatoires de l'intestin | |
| ATE248607T1 (de) | Aminotetralin derivate zur therapie der kardiovaskulären erkrankungen | |
| EA200702534A1 (ru) | Применение бензоильного производного 3-аминокарбазола для лечения расстройства, связанного с продукцией простагландина e2(pge2) | |
| MX2025012881A (es) | Compuestos heterociclicos biciclicos fusionados como moduladores del receptor tipo 4 de quimiocina c-c (ccr4) | |
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний |